Association between pretreatment Glasgow prognostic score and gastric cancer survival and clinicopathological features: a meta-analysis

Chun-Xiao Zhang*
Shu-Yi Wang*
Shuang-Qian Chen
Shuai-Long Yang
Lu Wan
Bin Xiong

Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuhan, Hubei, People’s Republic of China

*These authors contributed equally to this work

Background: Glasgow prognostic score (GPS) is widely known as a systemic inflammatory-based marker. The relationship between pretreatment GPS and gastric cancer (GC) survival and clinicopathological features remains controversial. The aim of the study was to conduct a meta-analysis of published studies to evaluate the association between pretreatment GPS and survival and clinicopathological features in GC patients.

Methods: We searched PubMed, Embase, MEDLINE, and BioMed databases for relevant studies. Combined analyses were used to assess the association between pretreatment GPS and overall survival, disease-free survival, and clinicopathological parameters by Stata Version 12.0.

Results: A total of 14 studies were included in this meta-analysis, including 5,579 GC patients. The results indicated that pretreatment high GPS (HGPS) predicted poor overall survival (hazard ratio = 1.51, 95% CI: 1.37–1.66, P < 0.01) and disease-free survival (hazard ratio = 1.45, 95% CI: 1.26–1.68, P < 0.01) in GC patients. Pretreatment HGPS was also significantly associated with advanced tumor–node–metastasis stage (odds ratio [OR] = 3.09, 95% CI: 2.11–4.53, P < 0.01), lymph node metastasis (OR = 3.04, 95% CI: 2.33–3.66, P < 0.01), lymphatic invasion (OR = 3.56, 95% CI: 1.81–6.99, P < 0.01), and venous invasion (OR = 3.56, 95% CI: 1.81–6.99, P < 0.01).

Conclusion: Our meta-analysis indicated that pretreatment HGPS could be a predictive factor of poor survival outcome and clinicopathological features for GC patients.

Keywords: Glasgow prognostic score, gastric cancer, survival, clinicopathological feature

Introduction

Gastric cancer (GC) is one of the most common cancers in the world.1 In recent years, although surgery, chemoradiotherapy, and targeted therapy make great progress to prolong survival of GC patients, GC is still the third leading cause of cancer-related death worldwide mainly because of tumor local recurrence and distant metastasis.2,3 Therefore, it is essential to identify GC patients with a high-risk of tumor recurrence and poor prognosis. For this purpose, both clinicians and researchers have made great efforts to seek practical biomarkers that can predict progression and survival in GC patients.

In the current clinical work, pathological tumor–node–metastasis (TNM) stage is a common predictive factor of predicting the prognosis and making treatment plans for GC patients, but heterogeneity of prognosis still exists in the same stage.3 This leaves a large space to search supplementary biomarkers for better predicting the prognosis of GC patients. It is increasingly recognized that variations within clinical outcomes in cancer patients were influenced by not only clinicopathological characteristics but also
the host systemic inflammatory response. The connection between systemic inflammatory response and tumors has been researched in both animal models and clinical trials in the past years.

Glasgow prognostic score (GPS) as an inflammation-based prognostic score is composed of serum C-reactive protein (CRP) and albumin level. The first study on GPS reported by Forrest et al. in 2003 showed that it could be an indicator of prognosis for non-small-cell lung cancer patients. Subsequently, increasing evidence revealed that GPS acquired its prognostic significance in patients with esophageal cancer, pancreatic cancer, colorectal cancer, and so on. Meanwhile, increased level of GPS could predict poor survival in GC patients. However, due to variance in the study design, some authors did not agree with the former results. The impact of GPS on GC patients’ prognosis still remains controversial. Thus, we searched the available studies and conducted this meta-analysis in order to evaluate the prognostic role of GPS in GC. The relationship between GPS and clinicopathological parameters was also investigated.

Materials and methods

Literature search

We searched PubMed, Embase, MEDLINE, and BioMed databases for studies that assessed the prognostic role of GPS for GC patients. The keywords used for research were “Glasgow prognostic score” or “GPS”, “survival” or “outcome”, “clinicopathological feature”, and “gastric cancer” or “stomach carcinoma”. The last search was updated in December 31, 2015. Additionally, potentially related articles were also retrieved by the references in the identified articles.

Study inclusion and exclusion criteria

Inclusion criteria for selecting the articles in our analysis were as follows: 1) studies in which the patients were diagnosed as GC based on pathological examination; 2) studies that investigated the association between pretreatment GPS and clinicopathological characteristics, overall survival (OS), and disease-free survival (DFS); 3) studies that were not directly reporting hazard ratio (HR) with its 95% confidence interval (CI) were allowed if we could reconstruct HR with its 95% CI by data reported; and 4) papers that were published in English. Exclusion criteria were as follows: 1) reviews, case reports, or laboratory studies; 2) studies without available full text or sufficient data for reconstructing HR with its 95% CI; and 3) studies containing duplicate data.

Data extraction

For each study, the following items were extracted: 1) first author, year of publication, country of the studied population, sample size, age, predominant treatment, and follow-up period; 2) clinicopathological parameters including TNM stage, lymph node metastasis, lymphatic invasion, venous invasion, differentiated degree, and carcinoembryonic antigen level; 3) survival data including OS and DFS; and 4) the cut-off value of GPS.

Quality assessment

Two reviewers (Chun-Xiao Zhang and Shu-Yi Wang) independently implemented quality assessment in the included studies by using the Newcastle–Ottawa Quality Assessment Scale (NOS). The NOS comprised three parameters of quality: selection (0–4 points), comparability (0–2 points), and outcome assessment (0–3 points). The maximum score is 9 points, and NOS scores of ≥6 were assigned as high-quality studies. Any disagreement was resolved by discussion.

Statistical analysis

HR with its 95% CI was obtained directly from each literature or estimated by data reported according to the methods illustrated by Parmar et al. For analyzing the correlation between GPS and clinicopathological parameters, odds ratio (OR) with its 95% CI was combined as the effective value. If both univariate and multivariate analyses were reported in the same study, multivariate analysis was chosen for the meta-analysis. Heterogeneity among pooled results was assessed using Cochran’s Q test and Higgins P statistic. P<0.10 and R>50% were considered the values that indicated significant heterogeneity, and the random-effects model was applied. If not, the fixed-effects model was performed. The potential publication bias was evaluated by Begg’s funnel plot and Egger’s linear regression test. The influence of publication bias on the overall effect was assessed by the “trim and fill” method described by Duval and Tweedie. All statistical analyses were two-sided, and the significant level was defined as 5%. Statistical analyses were performed by Stata Version 12.0 (StataCorp LP, College Station, TX, USA).

Results

Description of the included studies

According to the aforementioned search terms, 132 studies were retrieved. By intensively reading the potential articles, 118 studies were excluded. Lastly, 14 studies published between 2011 and 2015 were included in this meta-analysis.
Characteristics of included studies are summarized in Table 1. Fourteen retrospective studies were included containing 5,579 GC patients. Seven studies were from Japan, four from the People’s Republic of China, two from Korea, and one from Italy. The sample size of included articles ranged from 102 to 1,710 GC patients. The cut-off values of GPS were diverse, and GPS of 0 or 1 point was assigned for each CRP level less than or greater than the cut-off value (3 mg/L, 5 mg/L, or 10 mg/L) and albumin level greater than or less than the cut-off value (35 g/L or 38 g/L), aggregating score ranging from 0 to 2. GPS of 2 was defined as high GPS (HGPS), and GPS of 0 or 1 was defined as low GPS (LGPS). HR with its 95% CI was directly extracted as high GPS (HGPS), and GPS of 0 or 1 was defined as low GPS (LGPS). HR with its 95% CI was directly extracted from the original literature in 13 studies and estimated by aggregating score ranging from 0 to 2. GPS of 2 was defined as high GPS (HGPS), and GPS of 0 or 1 was defined as low GPS (LGPS). HR with its 95% CI was directly extracted from the original literature in 13 studies and estimated by aggregating score ranging from 0 to 2. GPS of 2 was defined as high GPS (HGPS), and GPS of 0 or 1 was defined as low GPS (LGPS). HR with its 95% CI was directly extracted from the original literature in 13 studies and estimated by aggregating score ranging from 0 to 2. GPS of 2 was defined as high GPS (HGPS), and GPS of 0 or 1 was defined as low GPS (LGPS). HR with its 95% CI.
| Study                  | Country         | Sample size | Predominant treatment | TNM | Follow-up (months)* | Cut-off value | No (GPS 0/1/2) | Survival analysis | NOS score |
|-----------------------|-----------------|-------------|------------------------|-----|---------------------|---------------|----------------|-------------------|------------|
| Aurello et al[6]      | Italy           | 102         | Surgery                | I–IV| 40.8 (8–107)        | CRP =10 mg/L; Alb = 35 g/L | 49/25/28       | OS, DFS            | 6               |
| Hirashima et al[7]    | Japan           | 294         | Surgery                | I–IV| 31.5 (1–91)         | CRP =5 mg/L; Alb = 38 g/L | 174/84/36       | OS                | 8               |
| Hwang et al[18]       | Korea           | 402         | Chemotherapy           | IV  | 11.4 (1.1–58.5)     | CRP =10 mg/L; Alb = 35 g/L | 238/111/53      | OS                | 6               |
| Ishizuka et al[19]    | Japan           | 425         | Surgery                | I–IV| 49.6 (0.3–147.6)    | CRP =10 mg/L; Alb = 35 g/L | 298/99/28       | OS                | 8               |
| Jeong et al[20]       | Korea           | 104         | Chemotherapy           | IV  | 11.9                | CRP =10 mg/L; Alb = 35 g/L | 58/29/17        | OS                | 6               |
| Jiang et al[11]       | Japan           | 1,710       | Surgery                | I–IV| 43 (1–123)          | CRP =10 mg/L; Alb = 35 g/L | 1,565/78/67     | OS                | 8               |
| Li et al[21]          | People's Republic of China | 384     | Chemotherapy           | II–IV| 13.9               | CRP =10 mg/L; Alb = 35 g/L | 145/66/5       | OS                | 6               |
| Liu et al[22]         | People's Republic of China | 455     | Surgery                | I–III| 25 (1–76)         | CRP =10 mg/L; Alb = 35 g/L | 350/92/13       | OS                | 7               |
| Mohri et al[23]       | Japan           | 197         | Surgery                | I–III| 51 (23–82)         | CRP =5 mg/L; Alb = 35 g/L | 114/53/30       | DFS               | 7               |
| Nozoe et al[24]       | Japan           | 232         | Surgery                | I–IV| 1.67–111           | CRP =10 mg/L; Alb = 35 g/L | 140/64/28       | OS                | 8               |
| Pan et al[25]         | People's Republic of China | 207     | Surgery                | I–IV| 37 (3–83)          | CRP =10 mg/L; Alb = 35 g/L | 103/71/33       | OS, DFS            | 6               |
| Takeno et al[22]      | Japan           | 552         | Surgery                | I–IV| NR                 | CRP =3 mg/L; Alb = 35 g/L | 411/75/66       | OS                | 8               |
| Tanaka et al[26]      | Japan           | 191         | Surgery                | IV  | 13.3               | CRP =10 mg/L; Alb = 35 g/L | 132/23/36       | OS, DFS            | 7               |
| Wang et al[27]        | People's Republic of China | 324     | Surgery                | III | 39.9 (23.8–57.4)   | CRP =10 mg/L; Alb = 35 g/L | 248/58/18       | OS, DFS            | 7               |

Note: *Median/range.
Abbreviations: GPS, Glasgow prognostic score; NOS, Newcastle–Ottawa Quality Assessment Scale; CRP, C-reactive protein; Alb, albumin; OS, overall survival; DFS, disease-free survival; NR, not reported.
Figure 2 The forest plot between pretreatment gPs and OS in GC patients.

Abbreviations: GPS, Glasgow prognostic score; OS, overall survival; GC, gastric cancer; HR, hazard ratio; CI, confidence interval; HGPS, high Glasgow prognostic score; lGPs, low Glasgow prognostic score.

Table 2 Results of subgroup analysis

| Subgroup                  | No of studies | Random-effects model         | Fixed-effects model          | Heterogeneity |
|---------------------------|---------------|------------------------------|-----------------------------|---------------|
|                           |               | HR (95% CI)                  | P-value                     | HR (95% CI)   | P-value | I² (%) | P-value |
| Predominant treatment     |               |                              |                             |               |         |        |         |
| Surgery                   | 10            | 1.46 (1.26–1.68)             | <0.01                       | 1.41 (1.26–1.58) | <0.01 | 27.3   | 0.19    |
| Chemotherapy              | 3             | 1.78 (1.48–2.13)             | <0.01                       | 1.78 (1.48–2.13) | <0.01 | 0.0    | 0.70    |
| Country                   |               |                              |                             |               |         |        |         |
| Japan                     | 6             | 1.66 (1.29–2.14)             | <0.01                       | 1.57 (1.28–1.93) | <0.01 | 23.4   | 0.26    |
| Other                     | 7             | 1.51 (1.30–1.77)             | <0.01                       | 1.49 (1.33–1.66) | <0.01 | 44.5   | 0.09    |
| Sample size               |               |                              |                             |               |         |        |         |
| <300                      | 6             | 1.73 (1.35–2.20)             | <0.01                       | 1.60 (1.34–1.92) | <0.01 | 28.7   | 0.22    |
| ≥300                      | 7             | 1.48 (1.27–1.73)             | <0.01                       | 1.47 (1.31–1.65) | <0.01 | 39.5   | 0.13    |
| NOS score                 |               |                              |                             |               |         |        |         |
| <7                        | 5             | 1.65 (1.41–1.92)             | <0.01                       | 1.64 (1.42–1.88) | <0.01 | 16.2   | 0.31    |
| ≥7                        | 8             | 1.46 (1.22–1.74)             | <0.01                       | 1.39 (1.22–1.59) | <0.01 | 30.6   | 0.18    |

Abbreviations: HR, hazard ratio; CI, confidence interval; NOS, Newcastle–Ottawa Quality Assessment Scale.

Figure 3 The forest plot between pretreatment gPs and DFS in GC patients.

Abbreviations: GPS, Glasgow prognostic score; DFS, disease-free survival; GC, gastric cancer; HR, hazard ratio; CI, confidence interval; HGPS, high Glasgow prognostic score; lGPs, low Glasgow prognostic score.
Figure 4 The forest plot between pretreatment GPS and clinicopathological parameters in GC.
Notes: (A) TnM stage (III vs I and II); (B) lymph node metastasis (positive vs negative); (C) lymphatic invasion (positive vs negative); and (D) venous invasion (positive vs negative). Weights are random-effects analysis.
Abbreviations: GPS, Glasgow prognostic score; GC, gastric cancer; TnM, tumor–node–metastasis; OR, odds ratio; CI, confidence interval; HGPS, high Glasgow prognostic score; LGPS, low Glasgow prognostic score.
only in OS ($P=0.04$ for Begg’s test and $P=0.02$ for Egger’s test; Figure 5A). Therefore, the “trim and fill” analysis was further performed. As a result, there were four studies hypothetically remained unpublished, and recalculated result did not change significantly (HR = 1.46, 95% CI: 1.33–1.60, $P<0.01$), indicating the stability of the result (Figure 5B).

### Discussion

Systemic inflammatory response played a crucial role in the development and progression of various tumors. Several biomarkers based on inflammation including GPS, neutrophil–lymphocyte ratio, and platelet–lymphocyte ratio had been reported to be independent prognostic predictors for cancer patients. However, it was not clear which of these biomarkers better predicted survival for GC patients.

Many recent studies indicated that pretreatment GPS was superior to other biomarkers in predicting survival in either operable GC patients or inoperable advanced GC patients. Besides, GPS, which is easily obtained by peripheral blood test before treatment, can give a preoperative risk assessment, whereas TNM stage and lymphovascular invasion give a postoperative risk assessment. Preoperative HGPS would identify patients at high risk of tumor recurrence and poor prognosis, helping clinicians to focus on these patients who would need more careful TNM stage, rigorous follow-up, and imperative adjuvant treatment. Pan et al showed that adjuvant chemotherapy after resection could significantly prolong OS and DFS in GC patients with LGPS, but not with HGPS. The result was similar to the study of Wang et al who reported that in stage III GC patients receiving adjuvant chemotherapy, there was a significant decrease in the median survival for those patients with HGPS comparing with those patients with LGPS, which suggested that patients with HGPS derived little survival benefit from active treatment. Therefore, GPS could not only simply represent the host systemic inflammatory response but also importantly be used to predict survival outcome and to individualize treatment plans for GC patients.

The results of our study revealed that pretreatment HGPS could predict poor OS and DFS in GC patients. Meanwhile, there was an obvious relationship between pretreatment HGPS and clinicopathological parameters, such as TNM stage, lymph node metastasis, lymphatic invasion, and venous invasion. According to the above-mentioned results, GPS is a promising prognostic biomarker of GC patients assisting in predicting prognosis and identifying treatment plans.

There were some limitations to this meta-analysis. First, language selection may bring bias. We have restricted our analysis to published studies written in English, other languages such as Japanese and Korean were excluded based on language criteria. This may result in language bias leading to an overestimation of effect sizes. Second, heterogeneity among included studies was observed in the results. This may be because of confounding factors, such as different characteristics of enrolled patients, sample size, treatment method, follow-up period, and cut-off value of GPS. We handled the issue of heterogeneity by a rigorous methodological approach that utilized random-effects model for more

### Table 3 Relationship between pretreatment GPS and differentiated degree and CEA level

| Factors                  | OR    | 95% CI       | $P$-value |
|--------------------------|-------|--------------|-----------|
| Differentiated degree    | 1.02  | 0.89–1.17    | 0.79      |
| CEA level                | 2.13  | 0.51–8.87    | 0.30      |

Notes: *Poor vs well or moderate, $^a$ $\geq$ 5 ng mL$^{-1}$ vs $<5$ ng mL$^{-1}$.

Abbreviations: GPS, Glasgow prognostic score; CEA, carcinoembryonic antigen; OR, odds ratio; CI, confidence interval.
conservative estimate. Moreover, the funnel plot analysis of OS showed some asymmetry, and publication bias was confirmed by Begg’s test and Egger’s test. Thus, the pooled result may be somehow overvalued. But the followed “trim and fill” analysis did not change the general result, which further reinforced the prognostic role of GPS in GC patients.

**Conclusion**

Our meta-analysis indicated that pretreatment HGPS, namely elevated CRP and reduced albumin level, was associated with poor survival and clinicopathological features in GC. It might be used as a prognostic biomarker for GC and figure out the high-risk patients who may not benefit from the anti-tumor therapies and consequently adjust treatment strategies. However, large-scale prospective investigations need to be conducted to better understand the prognostic role of GPS in GC patients.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *Cancer J Clin*. 2015;65(2):87–108.
2. Maehara Y, Kakeji Y, Oda S, Takahashi I, Akazawa K, Sugimachi K. Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. *Brit J Cancer*. 2000;83(8):986–991.
3. Peng CW, Wang LW, Zeng WJ, Yang XJ, Li Y. Evaluation of the staging systems for gastric cancer. *J Surg Oncol*. 2013;108(2):93–105.
4. MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. *J Support Oncol*. 2007;5(4):157–162; discussion 164–156, 183.
5. Coussens LM, Werb Z. Inflammation and cancer. *Nature*. 2002;420(6917):860–867.
6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. *Nature Biotechnol*. 2007;25(6):455–463.
7. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. *Brit J Cancer*. 2003;89(6):1028–1030.
8. Crumley ABC, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. *Brit J Cancer*. 2006;94(5):637–641.
9. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. *Pancreatology*. 2006;6(5):450–453.
10. McMillan DC, Crozier JEM, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. *Int J Colorectal Dis*. 2007;22(8):881–886.
11. Jiang X, Hiki N, Nunobe S, et al. Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. *Brit J Cancer*. 2012;107(2):275–279.
12. Takeno S, Hashimoto T, Shibuta R, et al. The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor in patients with resectable gastric cancer. *Oncology-Basel*. 2014;87(4):205–214.
13. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Stat Med*. 1998;17(24):2815–2834.
14. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*. 2010;25(9):603–605.
15. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*. 2000;56(2):455–463.
16. Aurello P, Tierno SM, Berardi G, et al. Value of preoperative inflammation-based prognostic scores in predicting overall survival and disease-free survival in patients with gastric cancer. *Ann Surg Oncol*. 2014;21(6):1998–2004.
17. Hirashima K, Watanabe M, Shigaki H, et al. Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer. *J Gastroenterol*. 2014;49(6):1040–1046.
18. Hwang JE, Kim HN, Kim DE, et al. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurrent or metastatic gastric cancer. *BMC Cancer*. 2011;11:489.
19. Ishizuka M, Oyama Y, Abe A, Tago K, Tanaka G, Kubota K. Clinical significance of an inflammation-based prognostic system for gastric cancer patients with a predictive normal serum level of carcinoembryonic antigen. *Anticancer Res*. 2014;34(12):7219–7226.
20. Jeong JH, Lim SM, Yun JY, et al. Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. *Oncology-Basel*. 2012;83(5):292–299.
21. Li QQ, Lu ZH, Yang L, et al. Neutrophil count and the inflammation-based Glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. *Asian Pac J Cancer Prev*. 2014;15(2):945–950.
22. Liu XC, Sun XW, Liu JJ, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. *Transl Oncol*. 2015;8(4):339–345.
23. Mohri Y, Tanaka K, Ohi M, et al. Inflammation-based prognostic score as a predictor of postoperative gastric cancer recurrence. *Anticancer Res*. 2012;32(10):4581–4584.
24. Nozoe T, Iguchi T, Egashira A, Adachi E, Matsukuma A, Ezaki T. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. *Am J Surg*. 2011;201(2):186–191.
25. Pan QX, Su ZJ, Zhang JH, Wang CR, Ke SY. A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer. *Onco Targets Ther*. 2015;8:1375–1385.
26. Tanaka H, Muruguma K, Toyokawa T, Kubo N, Ohira M, Hirakawa K. Differential impact of the neutrophil-lymphocyte ratio on the survival of patients with stage IV gastric cancer. *Digest Surg*. 2014;31(4–5):327–333.
27. Wang DS, Ren C, Qiu MZ, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. *Tumor Biol*. 2012;33(3):749–756.
28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646–674.
29. McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. *Cancer Treat Rev*. 2013;39(5):534–540.
30. Guthrie GJK, Roxburgh CSD, Horgan PG, McMillan DC. Does interleukin-6 link explain the link between tumour necrosis, local and systemic inflammatory responses and outcome in patients with colorectal cancer? *Cancer Treat Rev*. 2013;39(1):89–96.
31. Zhou X, Du YP, Huang ZB, et al. Prognostic value of PLR in various cancers: a meta-analysis. *PLoS One*. 2014;9(6):e101119.
32. Pham B, Klassen TP, Lawson ML, Moher D. Language of publication restrictions in systematic reviews gave different results depending on whether the intervention was conventional or complementary. *J Clin Epidemiol*. 2005;58(8):769–776.
